TRIM8

Across TCGA pan-cancer cohorts, TRIM8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRIM8 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TRIM8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRIM8 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where TRIM8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	III,IV	0.972	0.295	.006	28	view →
PDAC	OS	Median	III,IV	0.260	0.844	.024	6	view →
LUAD	DFS	Tertile	III,IV	0.554	0.995	.031	3	view →
HNSC	DFS	Median	All	0.801	0.973	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TRIM8–LSCC (DFS)

Open the LSCC breakdown →